Page last updated: 2024-10-21
4-aminopyridine and Granulocytic Leukemia, Chronic
4-aminopyridine has been researched along with Granulocytic Leukemia, Chronic in 1 studies
Research Excerpts
Excerpt | Relevance | Reference |
---|---|---|
" Second, we tested the therapeutic effect of VP16 combined with CCT245737, an orally bioavailable CHK1 inhibitor, and observed strong synergistic anticancer effects in K562 cells." | 1.56 | Checkpoint kinase‑1 inhibition and etoposide exhibit a strong synergistic anticancer effect on chronic myeloid leukemia cell line K562 by impairing homologous recombination DNA damage repair. ( Fan, Z; Lai, Q; Li, S; Liang, A; Luo, H; Wang, F; Wang, G; Wang, J; Xu, J; Xu, Y; Zhang, W; Zhou, J, 2020) |
Research
Studies (1)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Fan, Z | 1 |
Luo, H | 1 |
Zhou, J | 1 |
Wang, F | 1 |
Zhang, W | 1 |
Wang, J | 1 |
Li, S | 1 |
Lai, Q | 1 |
Xu, Y | 1 |
Wang, G | 1 |
Liang, A | 1 |
Xu, J | 1 |
Other Studies
1 other study available for 4-aminopyridine and Granulocytic Leukemia, Chronic
Article | Year |
---|---|
Checkpoint kinase‑1 inhibition and etoposide exhibit a strong synergistic anticancer effect on chronic myeloid leukemia cell line K562 by impairing homologous recombination DNA damage repair.
Topics: 4-Aminopyridine; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Chec | 2020 |